Results 11 to 20 of about 37,942 (184)

Factors associated with willingness to accept pneumococcal vaccine based on the Health Belief Model among the elderly (≥60 years) living in Klang Valley, Malaysia [PDF]

Human Vaccines & Immunotherapeutics
Understanding health behavior using the Health Belief Model (HBM) helps formulate strategies to improve the willingness, thereby increasing the acceptance of pneumococcal vaccination among the elderly.
Muhammad Faiz Mohd Hisham, Chandrashekhar T. Sreeramareddy   +1 more
doaj   +2 more sources

Cost-effectiveness analysis of a maternal pneumococcal vaccine in low-income, high-burden settings such as Sierra Leone [PDF]

PLOS Global Public Health, 2023
Maternal pneumococcal vaccines have been proposed as a method of protecting infants in the first few months of life. In this paper, we use results from a dynamic transmission model to assess the cost-effectiveness of a maternal pneumococcal ...
Gizem M. Bilgin, Syarifah Liza Munira, Kamalini Lokuge, Kathryn Glass   +3 more
doaj   +2 more sources

Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development [PDF]

Vaccines
Pneumococcal vaccines are a cornerstone for the prevention of pneumococcal diseases, reducing morbidity and mortality in children and adults worldwide.
Kristen Feemster, William P. Hausdorff, Natalie Banniettis, Heather Platt, Priscilla Velentgas, Alejandra Esteves-Jaramillo, Robert L. Burton, Moon H. Nahm, Ulrike K. Buchwald   +8 more
doaj   +2 more sources

Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults

Microorganisms, 2021
Pneumococcal disease is one of the most common and severe vaccine-preventable diseases (VPDs). Despite the advances in antimicrobial treatment, pneumococcal disease still remains a global burden and exhibits a high mortality rate among people of all ages
Nobuhiro Asai, Hiroshige Mikamo
doaj   +1 more source

A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older (STRIDE-6). [PDF]

Clin Infect Dis
Scott P, Haranaka M, Choi JH, Stacey H, Dionne M, Greenberg D, Grijalva CG, Orenstein WA, Fernsler D, Gallagher N, Zeng T, Li J, Platt HL, STRIDE-6 Study Group.   +13 more
europepmc   +2 more sources

Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine.

PLoS ONE, 2022
Pneumococcal conjugate vaccines reduce the burden of invasive pneumococcal disease, but the sustained effect of these vaccines can be diminished by an increase in disease caused by non-vaccine serotypes.
Sweta M Patel, Yazdani B Shaik-Dasthagirisaheb, Morgan Congdon, Rebecca R Young, Mohamed Z Patel, Tiny Mazhani, Sefelani Boiditswe, Tirayaone Leburu, Kwana Lechiile, Tonya Arscott-Mills, Andrew P Steenhoff, Kristen A Feemster, Samir S Shah, Coleen K Cunningham, Stephen I Pelton, Matthew S Kelly   +15 more
doaj   +3 more sources

A brief history of and future prospects for pneumococcal vaccination in Malaysia

Pneumonia, 2023
Pneumococcal pneumonia remains a significant global public health issue. Malaysia has recently added the 10 valent pneumococcal conjugate vaccine to its national immunisation programme.
Alex J. J. Lister, Evelin Dombay, David W. Cleary, Lokman H. Sulaiman, Stuart C. Clarke   +4 more
doaj   +1 more source

P-11. Assessing the Epidemiological Impact of an Age-Based Pneumococcal Vaccine Recommendation in France [PDF]

Open Forum Infect Dis
Kevin Bakker, Rachel J. Oidtman, Giulio Meleleo, Oluwaseun Sharomi, M Brunel, G. Farge, Jan E. Carette, Robert B. Nachbar   +7 more
europepmc   +2 more sources

Distribution and Variation of Serotypes and Pneumococcal Surface Protein A Clades of Streptococcus pneumoniae Strains Isolated From Adult Patients With Invasive Pneumococcal Disease in Japan

Frontiers in Cellular and Infection Microbiology, 2021
Pneumococcal surface protein A (PspA) is a surface protein of Streptococcus pneumoniae that may be a candidate antigen for new pneumococcal vaccines.
Bin Chang, Yuki Kinjo, Yuki Kinjo, Yuki Kinjo, Masatomo Morita, Kosuke Tamura, Hiroshi Watanabe, Yoshinari Tanabe, Koji Kuronuma, Jiro Fujita, Kengo Oshima, Takaya Maruyama, Shuichi Abe, Kei Kasahara, Junichiro Nishi, Tetsuya Kubota, Makoto Ohnishi, Shigeru Suga, Kazunori Oishi   +18 more
doaj   +1 more source

Pneumococcal Conjugate Vaccination Followed by Pneumococcal Polysaccharide Vaccination in Lung Transplant Candidates and Recipients

Transplantation Direct, 2020
Background. Pneumococcal conjugate vaccination as well as pneumococcal polysaccharide vaccination are recommended for lung transplant candidates and recipients, but the combination of these vaccines has not been extensively studied in these specific ...
Thijs W. Hoffman, MD, Bob Meek, PhD, Ger T. Rijkers, PhD, Jan C. Grutters, MD, PhD, Diana A. van Kessel, MD, PhD   +4 more
doaj   +1 more source